Antibody-Drug Conjugate– tag –
-
FDA Greenlights 24 Drugs in May 2026, Featuring AbbVie’s Decnupaz ADC and Shionogi’s Xocova COVID-19 Oral
BioWorld USA Overview The U.S. FDA approved 24 drugs in May 2026, marking the highest number of approvals in a single month this year, with eight being novel molecular entities (NMEs). This surge includes AbbVie's CD123-targeting antibod... -
FDA Greenlights Breakthrough TNBC Therapies, First-in-Class Hypertriglyceridemia Drug, and New Breast Cancer Maintenance Regimen
FDA USA Overview On June 24, 2026, the U.S. FDA announced pivotal approvals across several cancer and metabolic disease indications, introducing significant new therapeutic options. These include a breakthrough for triple-negative breast... -
Precision Science Fuels Biopharma M&A Surge: Q1 2026 Hits $65B+, Marking Industry’s ‘Full Recovery’
BioSpace / PwC, Pharmaceutical Technology / PwC USA Overview PwC's latest report declares the biopharma ecosystem 'fully recovered,' with Q1 2026 M&A deal values exceeding $65 billion, marking the largest quarter since 2020. This rob... -
Closing the Innovation Gap: Early CMC Risk Management and Robust Conjugation Strategies for ADCs and AOCs
Industry Publication Unknown Overview As Antibody-Drug Conjugates (ADCs) and Oligonucleotide-Drug Conjugates (AOCs) rapidly expand beyond oncology, early identification of Chemistry, Manufacturing, and Controls (CMC) risks and establishi... -
Antibody-Drug Conjugate (ADC) Field Enters Era of Diversification in 2025: 130 New ADC Candidates Advance to Clinical Development, Total Reaches 2,334
ChemExpress (citing Beacon ADC database) China Overview In 2025, the Antibody-Drug Conjugate (ADC) field experienced a significant paradigm shift, transitioning from platform validation to an era of diversification. The total number of t... -
FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use
FDA USA Overview The FDA's Center for Drug Evaluation and Research (CDER) is streamlining nonclinical studies for biologics and conjugated products, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers. For ADCs w... -
ABL Bio’s Bispecific EGFR/MUC1 ADC, ABL209, Progresses in US Phase 1 Trial, Preclinical Data Presented at World ADC Korea
Seoul Economic Daily South Korea Overview ABL Bio unveiled preclinical data for its bispecific ADC candidate, ABL209 (NEOK002), currently in US Phase 1 clinical trials, at the 5th World ADC South Korea 2026. ABL209 targets both EGFR and ... -
Dana-Farber Cancer Institute Demonstrates Long-Term Efficacy of Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer
Dana-Farber Cancer Institute Newsroom USA Overview The antibody-drug conjugate (ADC), sacituzumab govitecan, demonstrated long-term benefits as a first-line treatment for advanced triple-negative breast cancer (TNBC) compared to standard... -
Pfizer Seagen Initiates Global Phase 3 Trial for ADC ‘PF-XXX’ in Platinum-Resistant Ovarian Cancer
Clinical Trials Arena USA Overview Pfizer Seagen has initiated a global Phase 3 clinical trial for its investigational antibody-drug conjugate (ADC), 'PF-XXX,' in patients with platinum-resistant ovarian cancer. The trial aims to evaluat... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ...
